Abstract: Compounds of formula I: are antagonists of the human 5-HT2A receptor, and hence useful in treatment or prevention of a variety of neurological conditions.
Type:
Grant
Filed:
November 9, 2004
Date of Patent:
August 22, 2006
Assignee:
Merk Sharp & Dohme Ltd.
Inventors:
Mark Stuart Chambers, Neil Roy Curtis, Angus Murray MacLeod, Robert James Maxey, Helen Jane Szekeres